2017年4月6日,仅仅时隔27天,美国国家综合癌症网络(NCCN)在线发布乳腺癌临床实践指南(2017年第2版),全文仍为201页。
关于本版(2017年第2版)NCCN乳腺癌临床实践指南,更新不多,主要增加了若干CDK4/6抑制剂(利泊昔布、帕泊昔布)的推荐意见,具体如下:
浸润性乳腺癌-20(BINV-20) 增加利泊昔布+来曲唑(1类证据)用于既往1年内未接受任何内分泌疗法的绝经后患者。 Added ribociclib + letrozole as a category 1 option for postmenopausal patients with no prior endocrine therapy within 1 y. 修改脚注ggg:帕泊昔布或利泊昔布联合来曲唑可以考虑用于HER2阴性转移性乳腺癌。 Modified footnote ggg: 'Palbociclib or ribociclib in combination with letrozole may be considered in HER2-negative, metastatic breast cancer.'
浸润性乳腺癌-23、N(BINV-23、N) 修改脚注:如果在帕泊昔布一种CDK4/6抑制剂+来曲唑治疗期间有疾病进展,无数据支持其他帕泊昔布方案。同样,如果在依西美坦+依维莫司治疗期间有疾病进展,亦无数据支持其他依维莫司方案。 Modified the footnote: 'If there is disease progression while on palbociclib a CDK4/6 inhibitor + letrozole, there are no data to support an additional line of therapy with another palbociclib regimen. Likewise, if there is disease progression while on exemestane + everolimus, there are no data to support an additional line of therapy with another everolimus regimen.'
浸润性乳腺癌-N(BINV-N)
|